Status:
COMPLETED
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study was specifically designed to provide additional information on the mechanism of action of direct renin inhibition postulating the higher-level RAS cascade inhibition. The purpose of this st...
Eligibility Criteria
Inclusion
- Mean sitting systolic blood pressure ≥ 140 mmHg and \< 180 mmHg
- 24-hr mean ambulatory systolic blood pressure ≥ 135 mmHg
Exclusion
- Severe hypertension defined as mean sitting systolic blood pressure ≥ 180 mmHg and/or mean sitting diastolic blood pressure ≥ 110 mmHg
- Patients with Type 1 diabetes mellitus
- Secondary hypertension of any etiology
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
822 Patients enrolled
Trial Details
Trial ID
NCT00865020
Start Date
March 1 2009
End Date
June 1 2010
Last Update
July 22 2011
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Sorocaba, Brazil
2
Investigative Site
Gatineau, Canada
3
Investigative Site
Guayaquil, Ecuador
4
Investigative Site
Erfurt, Germany